I make a donation

APTITUDE

Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor

Terminée

Bourses ACTION & PHRA 2022

Colloquium "La cardiologie préventive : nouveautés" (mardi 1er avril 2025)
Réservez vos places !

La Fondation de l'AP-HP attribue le Grand Prix Scientifique 2024 au Pr Gilles Montalescot

La Grande Journée du Coeur (jeudi 26 juin 2025)
Réservez votre après-midi !

P&R Agenda
Au programme prochainement...

objectif

Monocentric, biological, prospective, ex-vivo, trial aiming at comparing the effects of in vivo platelet transfusion on platelet activation in patients with bleeding caused by aorto-coronary bypass, depending on the type of inhibitor of the P2Y12 receptor (clopidogrel, prasugrel or ticagrelor) and the effects of ex-vivo transfusion with un-treated PRP on the normalisation of the platelet reactivity in SCA/PCI patients after a dosis of clopidogrel, prasugrel ou ticagrelor.

date de réalisation

2014

nombre de patients

nombre de centres participants

Monocentric (Pitié-Salpêtrière)

type de financement

Public (INSERM) and private (ACTION Group)

Référence

n°301111, CNIL n°1547216v0

Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor : the APTITUDE study

Publication

Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P₂Y₁₂ inhibition by clopidogrel, prasugrel, and ticagrelor : the APTITUDE study
Stephen A O'Connor, Julien Amour, Anne Mercadier, Réjane Martin, Mathieu Kerneis, Jérémie Abtan, Delphine Brugier, Johanne Silvain, Olivier Barthélémy, Pascal Leprince, Gilles Montalescot, Jean-Philippe Collet, ACTION Study Group
Publicated in Circulation : Cardiovascular Interventions

Autres études

AFLOAT

En cours

To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.

ARGONAUT

En cours

Anticoagulant Regimens Given to achieve thrombus regression and reduce clinical Outcomes among patients with Non device related intra cardiac thrombus : a randomized Assessment Under direct oral antic...

AMUNDSEN

En cours

A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....